Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 0.81.

  • Lyell Immunopharma's Equity Ratio fell 587.01% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year decrease of 587.01%. This contributed to the annual value of 0.78 for FY2024, which is 1068.78% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Equity Ratio is 0.81, which was down 587.01% from 0.78 recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Equity Ratio ranged from a high of 0.89 in Q1 2023 and a low of 0.78 during Q2 2025
  • For the 5-year period, Lyell Immunopharma's Equity Ratio averaged around 0.84, with its median value being 0.84 (2022).
  • Per our database at Business Quant, Lyell Immunopharma's Equity Ratio soared by 35606.81% in 2021 and then plummeted by 1068.78% in 2024.
  • Lyell Immunopharma's Equity Ratio (Quarter) stood at 0.82 in 2021, then rose by 7.76% to 0.89 in 2022, then dropped by 1.75% to 0.87 in 2023, then dropped by 10.69% to 0.78 in 2024, then increased by 3.44% to 0.81 in 2025.
  • Its last three reported values are 0.81 in Q3 2025, 0.78 for Q2 2025, and 0.78 during Q1 2025.